Virtual consulting · Worldwide
NeuciteConsultingRequest a quote

Assay development and analytical method validation

Method drifting, an ELISA that will not repeat, or a validation or extractables study to plan? We design, troubleshoot and review analytical and bioanalytical methods against ICH Q2(R2). Your laboratory runs the work.

A result is only as good as the method behind it

Assay development turns a scientific question into a measurement you can trust. That means choosing the right technique, defining what the method must detect, and showing it works in your matrix. We support HPLC-UV, LC-MS and GC-MS methods, spectroscopic methods and immunoassays. We also help when an existing method gives inconsistent results. The aim is a method that suits its purpose and stands up to review.

Validation is planned from the start, not added at the end. ICH Q2(R2) sets out the performance characteristics to demonstrate: specificity or selectivity, range with its calibration model, accuracy, precision, and detection or quantitation limits where relevant. ICH Q14 describes how development knowledge, including robustness, supports that validation. We write a validation protocol that matches the method's intended use and stage of development.

Bioanalytical assays need extra care because biological matrices vary. Ligand-binding assays such as ELISA depend on reagent lots, plate effects, incubation conditions and curve fitting. When an assay measures drug or metabolite concentrations in study samples for a regulatory submission, ICH M10 sets the validation expectations. Biomarker assays fall outside M10's scope and are validated fit for purpose against their context of use. For research and screening assays, we define a lighter qualification with clear limits on how the data can be used.

For medical devices, chemistry also feeds safety. Extractables and leachables studies under ISO 10993-18 identify substances that may migrate from materials. Those data then feed a toxicological risk assessment under ISO 10993-17. We design these studies so that extraction conditions, analytical techniques and reporting thresholds fit together and answer the safety question.

What you receive

01

Method requirements definition

A short analytical target profile stating what the method must measure, in which matrix, over what range, and with what accuracy and precision. It anchors technique selection and later acceptance criteria.

02

Method development plan

Technique selection, column or antibody choice, sample preparation, detection and system suitability criteria, with the experiments needed to optimize them. Known matrix interferences and sample stability risks are addressed up front.

03

Troubleshooting report

For methods that drift or disagree between runs, a structured review of variation sources, from reagents and standards to peak integration and curve fitting. Corrective experiments are ranked by likely impact.

04

Validation protocol and review

A validation protocol with parameters, experiments and acceptance criteria matched to intended use. Once your laboratory has run it, we review the data and report against the protocol before sign-off.

05

Specification proposal

Proposed tests and limits for raw materials, extracts or finished products, linked to batch data, stability trends and method capability. Each limit comes with a written justification your quality team can defend.

06

E&L study plan

For devices, an extraction and analysis plan aligned with ISO 10993-18. It covers solvents, conditions, screening techniques, the analytical evaluation threshold, and how results pass to the toxicological risk assessment.

From question to routine method

Define the purpose

We clarify the decision the data will support: release testing, stability, bioanalysis, screening or safety. That purpose sets the required performance, the validation depth and the documentation your quality system will expect.

Develop and challenge

We design the development work and stress-test the method early. Deliberate changes to key conditions show where it is fragile. Problems found here cost far less than failures found in validation or routine use.

Validate and transfer

We write the validation protocol, review the data and support transfer to the laboratory that will run the method routinely. System suitability and control samples keep it performing after handover.

How this work typically looks

A

Nutraceutical manufacturer

Standardizing a herbal extract for consistent quality

Situation
A botanical extract varies from batch to batch in color, taste and assumed activity. The company sells it with a content claim but tests only total solids. A new buyer asks for a specification with identified marker compounds and a validated method.
How we advise
We review the plant's chemistry to choose active or analytical markers that are measurable and stable. We propose an HPLC-UV method with LC-MS confirmation of identity, plus a chromatographic fingerprint for consistency. We then write a validation protocol based on ICH Q2(R2) principles and propose specification limits from batch data and stability results.
What you receive
A marker selection rationale, an HPLC method outline, a validation protocol, and a draft specification with justified limits for identity, content and consistency.
B

Biotechnology company

ELISA results that will not repeat between runs

Situation
An in-house ELISA gives acceptable results within a plate but shifts between days and analysts. Control values drift, and some samples change classification on retest. The team cannot tell whether the biology or the assay is varying.
How we advise
We review the assay end to end: antibody and conjugate lots, coating, blocking, washing, incubation time and temperature, plate edge effects and the curve-fitting model. We design experiments to separate the main sources of variation. We then set out a qualification covering precision, dilutional linearity, parallelism and spike recovery, with run acceptance rules based on controls.
What you receive
A variability analysis, corrective actions in priority order, a qualification protocol, and run acceptance criteria that flag a failing plate before results are reported.
C

Medical device developer

Planning a device extractables study that answers the right question

Situation
A developer of a long-term contact device must provide chemical characterization data. A previous laboratory quote lists many tests but no rationale. The team does not know which extraction conditions apply or how to judge whether detected compounds matter.
How we advise
We map materials, contact type and duration to the extraction approach under ISO 10993-18. We specify polar, semi-polar and non-polar solvents as appropriate, with GC-MS, LC-MS and ICP-MS screening for volatile, semi-volatile, non-volatile and elemental species. We derive the analytical evaluation threshold from a dose-based threshold and explain how findings feed the ISO 10993-17 assessment.
What you receive
A study plan with justified extraction conditions, analytical techniques, thresholds and reporting requirements, ready to send to laboratories for comparable quotes.

Illustrative scenarios. Each is a composite of common client situations, not a specific engagement.

Frequently asked questions

Who performs the testing?

Testing is performed by your in-house laboratory or a contract laboratory you choose. We can help you write the request for quotation and compare laboratories on technique, accreditation and capacity. We design the methods and studies, then review the data against the decision it must support.

Do you handle ELISA assay development from scratch?

Yes, as design and troubleshooting support. We help choose the format, such as sandwich or competitive, select antibody pairs and plan titration, blocking and washing experiments. We define standards, controls and the curve-fitting model. Where the ELISA will measure drug concentrations for pharmacokinetic or toxicokinetic data in a regulatory submission, we plan validation against ICH M10. Biomarker assays are validated fit for purpose instead.

How is analytical method validation different from qualification?

Validation shows, against predefined criteria, that a method is suitable for its intended use, typically release, stability or regulated bioanalysis. Qualification is a lighter, fit-for-purpose assessment, often used in early development or for research assays. Both need a written plan. We advise which applies and when an early method must be fully validated.

What do you need from us to start?

Tell us what the method must measure and why, the sample matrix, the expected concentration range and the regulatory context. Share existing methods, chromatograms, raw data and reference standard sources. For extractables work, we need materials of construction, processing aids, contact type and duration. Timing depends mainly on how much development the method still needs.

What happens after the plan is delivered?

Your laboratory runs the development or validation work. We stay available to interpret unexpected results and to review the final report against the protocol. Many clients then ask us to draft specifications or plan stability testing that uses the new method. Each piece is scoped separately.

What happens after I contact you?

A scientist follows up by email about what the method must measure, the sample matrix, the regulatory context, and your current data. We confirm the materials needed and send a written quote for your approval.

Need a method you can trust?

Tell us what you need to measure and what is going wrong today. We’ll follow up by email and prepare a written quote for the method plan.

We design methods and studies and review data; testing is performed by your chosen laboratories, and validation approval and release decisions remain with your quality unit.